RAC1 expression increases with the tumour progression, and hyperactivation and/or overexpression are associated with a very poor prognosis23, while, on the contrary, ZNF750 levels significantly decrease with the breast cancer stage and negatively correlate with cancer aggressiveness. Here, RAC1 is linked to cancer.